Scolaris Content Display Scolaris Content Display

Eritromicina para la prevención de la enfermedad pulmonar crónica en recién nacidos prematuros intubados con riesgo de Ureaplasma urealyticum o ya colonizados o infectados por este microorganismo

Contraer todo Desplegar todo

Referencias

References to studies included in this review

Ir a:

Jonsson 1998 {published and unpublished data}

Jonsson B, Rylander M, Faxelius G. Ureaplasma urealyticum, erythromycin and respiratory morbidity in high‐risk preterm neonates. Acta Paediatr 1998;87:1079‐84. [MEDLINE: 99041350]

Lyon 1998 {published and unpublished data}

Lyon AJ, McColm J, Middlemist L, Fergusson S, McIntosh N, Ross PW. Randomised trial of erythromycin on the development of chronic lung disease in preterm infants. Arch Dis Child Fetal Neonatal Ed 1998;78:F10‐14. [MEDLINE: 98197901]

References to studies excluded from this review

Ir a:

Agarwal 2000 {published data only}

Agarwal P, Rajadurai VS, Pradeepkumar VK, Tan KW. Ureaplasma urealyticum and its association with chronic lung disease in Asian neonates. J Paediatr Child Hlth 2000;36:487‐90. [MEDLINE: 20488278]

Alfa 1995 {published data only}

Alfa MJ, Embree JE, Degagne P, Olson N, Lertzman J, Macdonald KS, Macdonald NT, Hall PF. Transmission of Ureaplasma urealyticum from mothers to full and preterm infants. Pediatr Infect Dis J 1995;14:341‐5. [MEDLINE: 95365164]

Bowman 1998 {published data only}

Bowman ED, Dharmalingam A, Fan WQ, Brown F, Garland SM. Impact of erythromycin on respiratory colonization of Ureaplasma urealyticum and the development of chronic lung disease in extremely low birth weight infants. Pediatr Infect Dis J 1998;17:615‐20. [MEDLINE: 98349517]

Cordero 1994 {published and unpublished data}

Cordero L, Warner W, Ayers L. Ureaplasma urealyticum tracheal colonization of mechanically ventilated newborn (abstract). Pediatr Res 1994;35:267A.

Cordero 1996 {published data only}

Cordero L, Davis K, Warner D, Ayers L. Ureaplasma urealyticum tracheal colonization and respiratory disease in newborn. Neonatal Intensive Care 1996;9:24‐31.

Da Silva 1997 {published data only}

Da Silva O, Gregson D, Hammerberg O. Role of Ureaplasma urealyticum and Chlamydia trachomatis in development of bronchopulmonary dysplasia in very low birth weight infants. Pediatr Infect Dis J 1997;19:364‐9. [97262929]

Galetto Lacour 2001 {published data only}

Galetto Lacour A, Zamora S, Bertrand R, Brighi Perret L, Auckenthaler R, Berner M, Suter S. Colonization by Ureaplasma urealyticum and chronic lung disease in premature newborn infants under 32 weeks of gestation. Arch Pediatr 2001;8:39‐46. [MEDLINE: 21087141]

Garland 1996 {published data only}

Garland SM, Bowman ED. Role of Ureaplasma urealyticum and Chlamydia trachomatis in lung disease in low birth weight infants. Pathology 1996;28:266‐69. [MEDLINE: 97069208]

Heggie 1994 {published data only}

Heggie AD, Jacobs MR, Butler VT, Baley JE, Boxerbaum B. Frequency and significance of isolation of Ureaplasma urealyticum and Mycoplasma hominis from cerebrospinal fluid and tracheal aspirate specimens from low birth weight infants. J Pediatr 1994;124:956‐61.

Izraeli 1991 {published data only}

Izraeli S, Samra Z, Sirota L, Merlob P, Davidson S. Genital mycoplasmas in preterm infants: prevalence and clinical significance. Eur J Pediatr 1991;150:804‐7.

Pacifico 1997 {published data only}

Pacifico L, Panero A, Roggini M, Rossi N, Bucci G, Chiesa C. Ureaplasma urealyticum and pulmonary outcome in a neonatal intensive care population. Pediatr Infect Dis J 1997;16:579‐86. [MEDLINE: 97337368]

Patterson 1998 {published data only}

Patterson AM, Taciak V, Lovchik J, Fox RE, Campbell AB, Viscardi RM. Ureaplasma urealyticum respiratory tract colonization is associated with an increase in interleukin 1‐beta and tumor necrosis factor alpha relative to interleukin 6 in tracheal aspirates of preterm infants. Pediatr Infect Dis J 1998;17:321‐8. [MEDLINE: 98235922]

Rudd 1984 {published data only}

Rudd PT, Carrington D. A prospective study of chlamydial, mycoplasmal, and viral infections in a neonatal intensive care unit. Arch Dis Child 1984;59:120‐5. [MEDLINE: 84152914]

Sanchez 1988 {published data only}

Sanchez PJ, Regan JA. Ureaplasma urealyticum colonization and chronic lung disease in low birth weight infants. Pediatr Infect Dis J 1988;7:542‐6. [MEDLINE: 94002812]

Tay 1997 {published data only}

Tay ST, Boo NY, Khoo TB, Koay AS, Rohani MY. Prevalence and antibiotic susceptibility of Ureaplasma urealyticum in Malaysian neonates with respiratory distress. Med J Malaysia 1997;52:409‐11. [20423828]

References to studies awaiting assessment

Ir a:

Okura 1998 {published data only}

Okura M, Sato Y, Takeuchi Y, Ono T, Hashimoto T, Nishigaki K. Multicenter study on clinical effects of a small dose of erythromycin on chronic lung disorders of premature infants‐single blind comparison of treated and treated groups. A committee for the Study of EM Therapy for Chronic Lung Disease of Premature Infants. Jpn J Antibiot 1998;51 Suppl 1:103‐6. [MEDLINE: 98259788]

Blanchard 1993

Blanchard A, Hentschel J, Duffy L, Baldus K, Cassell GH. Detection of Ureaplasma urealyticum by polymerase chain reaction in the urogenital tract of adults, in amniotic fluid, and in the respiratory tract of newborns. Clin Infect Dis 1993;17:S148‐53. [MEDLINE: 8399906]

Buhrer 2001

Buhrer C, Hoehn T, Hentschel J. Role of erythromycin for treatment of incipient chronic lung disease in preterm infants colonised with Ureaplasma urealyticum. Drugs 2001;61:1893‐99. [MEDLINE: 21565088]

Cassell 1988a

Cassell GH, Crouse DT, Waites KB, et al. Does Ureaplasma urealyticum cause respiratory disease in newborns?. Pediatr Infect Dis J 1988;7:535‐41.

Cassell 1988b

Cassell GH, Waites KB, Crouse DT, et al. Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very‐low‐birth‐weight infants. Lancet 1988;2:240‐5.

Cassell 1991

Cassell GH, Waites KB, Crouse DT. Perinatal mycoplasmal infections. Clin Perinatol 1991;18:241‐62. [MEDLINE: 91347616]

Cassell 2001

Cassell GH, Waites KB, Crouse DT. Mycoplasmal infections. In: Remington JS, Klein JO editor(s). Infectious Diseases of the Fetus and Newborn Infant. 5th Edition. Philadelphia: Saunders, 2001:733‐67.

Crouse 1993

Crouse DT, Odrezin GT, Cutter GR, Reese JM, Hamrick WB, Waites KB, Cassell GH. Radiographic changes associated with tracheal isolation of Ureaplasma urealyticum from neonates. Clin Infect Dis 1993;17 Suppl 1:S122‐30. [MEDLINE: 94002815]

Cunliffe 1996

Cunliffe NA, Fergusson S, Davidson F, Lyon A, Ross PW. Comparison of culture with the polymerase chain reaction for detection of Ureaplasma urealyticum in endotracheal aspirates of preterm infants. J Med Microbiol 1996;45:27‐30. [96281635]

Dinsmoor 1989

Dinsmoor MJ, Ramamurthy RS, Gibbs RS. Transmission of genital mycoplasmas from mother to neonate in women with prolonged membrane rupture. Pediatr Infect Dis J 1989;8:483‐7.

Forgacs 1993

Forgacs P, Kundsin RB, Margles SW, Silverman ML, Perkins RE. A case of Ureaplasma urealyticum septic arthritis in a patient with hypogammaglobulinemia. Clin Infect Dis 1993;16:293‐4. [MEDLINE: 93184109]

Garland 1987

Garland SM, Murton LJ. Neonatal meningitis caused by Ureaplasma urealyticum. Pediatr Infect Dis J 1987;6:868‐70. [MEDLINE: 88040244]

Grenabo 1988

Grenabo L, Hedelin H, Pettersson S. Urinary infections caused by Ureaplasma urealyticum: a review. Scand Infect Dis Suppl 1988;53:46‐9.

Hannaford 1999

Hannaford K, Todd DA, Jeffery H, John E, Blyth K, Gilbert GL. Role of Ureaplasma urealyticum in lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed 1999;81:F162‐7. [MEDLINE: 99455075]

Heggie 2001

Heggie AD, Bar‐shain D, Boxerbaum B, Fanaroff A, et al. Identification and quantification of ureaplasmas colonizing the respiratory tract and assessment of their role in the development of chronic lung disease in preterm infants. Pediatr Infect Dis J 2001;20:854‐9.

Honein 1999

Honein MA, Paulozzi LJ, Himelright IM, Lee B, Cragan JD, Patterson L, Correa A, Hall S, Erickson JD. Infantile hypertrophic pyloric stenosis after pertussis prophylaxis with erythromycin: a case review and cohort study. Lancet 1999;354:2101‐5. [MEDLINE: 20075905]

Horowitz 1992

Horowitz S, Landau D, Shinwell ES, Zmora E, Dagan R. Respiratory tract colonization with Ureaplasma urealyticum and bronchopulmonary dysplasia in neonates in southern Israel. Pediatr Infect Dis J 1992;11:847‐51. [MEDLINE: 93026841]

Iles 1996

Iles R, Lyon A, Ross P, McIntosh N. Infection with Ureaplasma urealyticum and Mycoplasma hominis and the development of chronic lung disease in preterm infants. Acta Paediatr 1996;85:482‐4. [MEDLINE: 96312754]

Iles 1997

Iles R, Edmunds AT. Assessment of pulmonary function in resolving chronic lung disease of prematurity. Arch Dis Child 1997;76:F113‐17. [MEDLINE: 97280982]

Kenyon 2002

Kenyon S, Boulvain M, Neilson J. Antibiotics for preterm premature rupture of membranes. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD001058]

McCormack 1986a

McCormack WM, Rosner B, Alpert S, Evrard JR, Crockett VA, Zinner SH. Vaginal colonization with Mycoplasma hominis and Ureaplasma urealyticum. Sex Transm Dis 1986;13:67‐70. [MEDLINE: 86235930]

McCormack 1986b

McCormack WM. Ureaplasma urealyticum: ecologic niche and epidemiologic considerations. Pediatr Infect Dis 1986;5:S232‐3. [MEDLINE: 87092014]

Mohiuddin 1991

Mohiuddin AA, Corren J, Harbeck RJ, Teague JL, Volz M, Gelfand EW. Ureaplasma urealyticum chronic osteomyelitis in a patient with hypogammaglobulinemia. J Allergy Clin Immunol 1991;87:104‐7. [MEDLINE: 91123588]

Northway 1967

Northway WHJ, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline‐membrane disease. Bronchopulmonary dysplasia. N Engl J Med 1967;276:357‐68. [MEDLINE: 67087240]

Ollikainen 2001

Ollikainen J, Korppi M, Heiskanen‐Kosma T, Heinonen K. Chronic lung disease of the newborn is not associated with Ureaplasma urealyticum. Pediatr Pulmonol 2001;32:303‐7.

Payne 1993

Payne NR, Steinberg SS, Ackerman P, Chrenka BA, Sane SM, Anderson KT, Fangman JJ. New prospective studies of the association of Ureaplasma urealyticum colonization and chronic lung disease. Clin Infect Dis 1993;17 Suppl 1:S117‐21. [MEDLINE: 94002814]

Perzigian 1998

Perzigian RW, Adams JT, Weiner GM, Dipietro MA, Blythe LK, Pierson CL, Faix RG. Ureaplasma urealyticum and chronic lung disease in very low birth weight infants during the exogenous surfactant era. Pediatr Infect Dis J 1998;17:620‐5. [MEDLINE: 98349518]

Sanchez 1987

Sanchez PJ, Regan JA. Vertical transmission of Ureaplasma urealyticum in full term infants. Pediatr Infect Dis J 1987;6:825‐8.

Sanchez 1988

Sanchez PJ, Regan JA. Ureaplasma urealyticum colonization and chronic lung disease in low birthweight infants. Pediatr Infect Dis J 1988;7:542‐46.

Sanchez 1990

Sanchez PJ, Regan JA. Vertical transmission of Ureaplasma urealyticum from mothers to preterm infants. Pediatr Infect Dis J 1990;9:398‐401.

Saxen 1993

Saxen H, Hakkarainen K, Pohjavuori M, Miettinen A. Chronic lung disease of preterm infants in Finland is not associated with Ureaplasma urealyticum colonization. Acta Paediatr 1993;82:198‐201. [MEDLINE: 93237720]

Shennan 1988

Shennan AT, Dunn MS, Ohlsson A, Lennox K, Hoskins EM. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics 1988;82:527‐32. [MEDLINE: 89016326]

Smyth 1993

Smyth AR, Shaw NJ Pratt BC, Weindling AM. Ureaplasma urealyticum and chronic lung disease. Eur J Pediatr 1993;152:931‐2. [MEDLINE: 94102311]

Stancombe 1993

Stancombe BB, Walsh WF, Derdak S, Dixon P, Hensley D. Induction of human neonatal pulmonary fibroblast cytokines by hyperoxia and Ureaplasma urealyticum. Clin Infect Dis 1993;17:S154‐7. [MEDLINE: 94002820]

Syrogiannopoulos '90

Syrogiannopoulos GA, Kapatais‐Zoumbos K, Decavalas GO, et al. Ureaplasma urealyticum colonization of full term infants: perinatal acquisition and persistence during early infancy. Pediatr Infect Dis J 1990;9:236‐40.

Tully 1993

Tully JG. Current status of the Mollicute flora of humans. Clin Infect Dis 1993;17 Suppl 1:S2‐9.

van Waarde 1997

van Waarde WM, Brus F, Okken A, Kimpen JL. Ureaplasma urealyticum colonization, prematurity and bronchopulmonary dysplasia. Eur Respir J 1997;10:886‐90. [MEDLINE: 97294573]

Waites 1989

Waites KB, Crouse DT, Philips JB, Canupp KC, Cassell GH. Ureaplasmal pneumonia and sepsis associated with persistent pulmonary hypertension of the newborn. Pediatrics 1989;83:79‐85. [MEDLINE: 89083363]

Wang 1988

Wang EE, Frayha H, Watts J, et al. Role of Ureaplasma urealyticum and other pathogens in the development of chronic lung disease of prematurity. Pediatr Infect Dis J 1988;7:547‐51.

Wang 1995

Wang EE, Ohlsson A, Kellner JD. Association of Ureaplasma urealyticum colonization with chronic lung disease of prematurity: results of a metaanalysis. J Pediatr 1995;127:640‐4. [MEDLINE: 96006287]

Characteristics of studies

Characteristics of included studies [ordered by study ID]

Ir a:

Jonsson 1998

Methods

Quasi ‐ randomized (alternate assignment). Concealed randomization‐ No. Masked intervention‐No (placebo not used). Complete follow‐up‐Yes. Masked outcome‐No.

Participants

28 intubated preterm infants <30 weeks gestation culture positive for U. urealyticum. 14 treated, 14 control

Interventions

Treated every other colonized infant with a 10 day course of erythromycin, 40 mg/kg/day, orally (n=10) or intravenously (n=4). Average age at treatment 7 days. Controls received no treatment.

Outcomes

Primary outcome: Oxygen dependency at 36 weeks PMA. Secondary outcome: Side effects of erythromycin treatment (GI, hepatic, cardiovascular)

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

High risk

C ‐ Inadequate
Lyon 1998

Methods

Randomized trial
(sealed envelopes). Concealed randomization ‐
Yes. Masked intervention‐No (placebo not used). Complete follow‐up‐Yes. Masked outcome‐Yes.

Participants

75 intubated infants equal to or less than 30 weeks gestation. Of the 75 randomized infants, 9 infants proved to be positive for U. urealyticum by culture and/or PCR.

Interventions

Erythromycin (45 mg/kg/day TID, IV for 7 days) treatment versus no treatment before culture/PCR results were known.
Cytokine levels and differential counts done on bronchoalveolar lavage.

Outcomes

Primary outcome: Inflammatory cytokine response after birth in bronchoalveolar lavage fluid.

Notes

Risk of bias

Bias

Authors' judgement

Support for judgement

Allocation concealment?

Low risk

A ‐ Adequate

Characteristics of excluded studies [ordered by study ID]

Ir a:

Study

Reason for exclusion

Agarwal 2000

No control group.

Alfa 1995

Treatment was not randomized.

Bowman 1998

No control group.

Cordero 1994

Treatment was not randomized.

Cordero 1996

Treatment was not randomized.

Da Silva 1997

Treatment was not randomized.

Galetto Lacour 2001

Treatment was not randomized.

Garland 1996

Treatment was not randomized.

Heggie 1994

Treatment was not randomized.

Izraeli 1991

Treatment was not randomized.

Pacifico 1997

Treatment was not randomized.

Patterson 1998

Treatment was not randomized.

Rudd 1984

No treatment with erythromycin was involved.

Sanchez 1988

No treatment with erythromycin was involved.

Tay 1997

No treatment with erythromycin was involved.

Characteristics of studies awaiting assessment [ordered by study ID]

Ir a:

Okura 1998

Methods

Not known

Participants

Not known

Interventions

Not known

Outcomes

Not known

Notes

Data and analyses

Open in table viewer
Comparison 1. Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 CLD Show forest plot

1

75

Risk Ratio (M‐H, Fixed, 95% CI)

1.40 [0.72, 2.70]
Analysis 1.1
Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 1 CLD.

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 1 CLD.

1.1 Culture/PCR positive

1

9

Risk Ratio (M‐H, Fixed, 95% CI)

2.0 [0.18, 22.06]

1.2 Culture/PCR negative

1

66

Risk Ratio (M‐H, Fixed, 95% CI)

1.35 [0.68, 2.69]

2 Death Show forest plot

1

75

Risk Ratio (M‐H, Fixed, 95% CI)

0.64 [0.22, 1.83]
Analysis 1.2
Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 2 Death.

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 2 Death.

2.1 Culture/PCR positive

1

9

Risk Ratio (M‐H, Fixed, 95% CI)

0.58 [0.03, 11.21]

2.2 Culture/PCR negative

1

66

Risk Ratio (M‐H, Fixed, 95% CI)

0.65 [0.21, 2.00]

3 CLD or death Show forest plot

1

75

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.66, 1.69]
Analysis 1.3
Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 3 CLD or death.

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 3 CLD or death.

3.1 Culture/PCR positive

1

9

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.14, 7.10]

3.2 Culture/PCR negative

1

66

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.66, 1.72]

4 Side effects of erythromycin Show forest plot

1

75

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]
Analysis 1.4
Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 4 Side effects of erythromycin.

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 4 Side effects of erythromycin.

Open in table viewer
Comparison 2. Erythromycin vs placebo in U. Urealyticum culture positive babies

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 CLD Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.9 [0.54, 1.50]
Analysis 2.1
Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 1 CLD.

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 1 CLD.

2 Death Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]
Analysis 2.2
Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 2 Death.

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 2 Death.

3 CLD or death Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.9 [0.54, 1.50]
Analysis 2.3
Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 3 CLD or death.

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 3 CLD or death.

4 Side effects of erythromycin Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]
Analysis 2.4
Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 4 Side effects of erythromycin.

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 4 Side effects of erythromycin.

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 1 CLD.
Figuras y tablas -
Analysis 1.1

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 1 CLD.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 2 Death.
Figuras y tablas -
Analysis 1.2

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 2 Death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 3 CLD or death.
Figuras y tablas -
Analysis 1.3

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 3 CLD or death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 4 Side effects of erythromycin.
Figuras y tablas -
Analysis 1.4

Comparison 1 Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection, Outcome 4 Side effects of erythromycin.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 1 CLD.
Figuras y tablas -
Analysis 2.1

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 1 CLD.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 2 Death.
Figuras y tablas -
Analysis 2.2

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 2 Death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 3 CLD or death.
Figuras y tablas -
Analysis 2.3

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 3 CLD or death.

Ir a la figura de la revisiónAbrir en una pestaña nueva

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 4 Side effects of erythromycin.
Figuras y tablas -
Analysis 2.4

Comparison 2 Erythromycin vs placebo in U. Urealyticum culture positive babies, Outcome 4 Side effects of erythromycin.

Ir a la figura de la revisiónAbrir en una pestaña nueva
Comparison 1. Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 CLD Show forest plot

1

75

Risk Ratio (M‐H, Fixed, 95% CI)

1.40 [0.72, 2.70]

1.1 Culture/PCR positive

1

9

Risk Ratio (M‐H, Fixed, 95% CI)

2.0 [0.18, 22.06]

1.2 Culture/PCR negative

1

66

Risk Ratio (M‐H, Fixed, 95% CI)

1.35 [0.68, 2.69]

2 Death Show forest plot

1

75

Risk Ratio (M‐H, Fixed, 95% CI)

0.64 [0.22, 1.83]

2.1 Culture/PCR positive

1

9

Risk Ratio (M‐H, Fixed, 95% CI)

0.58 [0.03, 11.21]

2.2 Culture/PCR negative

1

66

Risk Ratio (M‐H, Fixed, 95% CI)

0.65 [0.21, 2.00]

3 CLD or death Show forest plot

1

75

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.66, 1.69]

3.1 Culture/PCR positive

1

9

Risk Ratio (M‐H, Fixed, 95% CI)

1.0 [0.14, 7.10]

3.2 Culture/PCR negative

1

66

Risk Ratio (M‐H, Fixed, 95% CI)

1.06 [0.66, 1.72]

4 Side effects of erythromycin Show forest plot

1

75

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 1. Prophylactic erythromycin vs placebo in babies at risk for U. Urealyticum colonization or infection
Ir a la tabla de la revisión
Comparison 2. Erythromycin vs placebo in U. Urealyticum culture positive babies

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 CLD Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.9 [0.54, 1.50]

2 Death Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3 CLD or death Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.9 [0.54, 1.50]

4 Side effects of erythromycin Show forest plot

1

28

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]
Figuras y tablas -
Comparison 2. Erythromycin vs placebo in U. Urealyticum culture positive babies
Ir a la tabla de la revisión